MedTrace Logo

LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis

NCT03254667 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 3500

Last updated 2025-09-16

No results posted yet for this study

Summary

Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis

Conditions

Interventions

BIOLOGICAL

Brodalumab

Brodalumab

DRUG

Comparator Drug (non-biologic IL-17 inhibitors)

Comparator subjects treated with non-biologic IL-17 inhibitors

Sponsors & Collaborators

  • Bausch Health Americas, Inc.

    lead INDUSTRY

Principal Investigators

  • Varsha Bhatt · Bausch Health

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-25
Primary Completion
2030-11-10
Completion
2031-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03254667 on ClinicalTrials.gov